Publications by authors named "Shichao Deng"

2 Publications

  • Page 1 of 1

Lung cancer-associated T cell repertoire as potential biomarker for early detection of stage I lung cancer.

Lung Cancer 2021 Dec 28;162:16-22. Epub 2021 Sep 28.

Department of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Central South University, China; Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Changsha, China; Center for Molecular Medicine, Xiangya Hospital, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Changsha, China. Electronic address:

Background: Early detection of lung cancer in asymptomatic patients remains challenging, especially for stage I. Considering the substantial interaction with tumor immunogenicity, we hypothesized that lung cancer-associated TCR (LC-aTCR) may serve as potential biomarker in early detection of stage I lung cancer.

Methods: Individuals who received low-dose computed tomography (LDCT) screening were enrolled in the study. Surgical tissues and peripheral blood specimens were collected and performed with DNA-based T cell repertoire (TCR) sequencing. The motif-based algorithm was used to deconstruct specific lung cancer-associated TCRs (LC-aTCRs).

Results: A total of 146 individuals participating in the real-world LDCT screening project were enrolled in this study, including 52 patients with pathologically-confirmed stage I lung cancer and 94 non-cancer controls. We developed a motif-based algorithm to define 80 LC-aTCRs in the training cohort. Moreover, in the validation cohort, high sensitivity and specificity was showed in stage I lung cancer with 72% and 91% respectively, and the AUC of the ROC curve was 0.91 (95% CI: 0.85 ∼ 0.96).

Conclusion: This work provides inspiration for stage I lung cancer detection by using blood TCR profiling data. The combination of TCR-based assay and routine screening deserves further testing in larger cohorts.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2021.09.017DOI Listing
December 2021

The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients.

Cancer Med 2020 01 10;9(1):84-93. Epub 2019 Nov 10.

Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China.

Objective: KRAS mutation plays a critical role in the initiation and development of non-small cell lung cancer (NSCLC). KRAS-mutant patients exhibit diverse response to chemotherapy. KRAS co-mutation subtypes and their prognosis value in advanced Chinese NSCLC patients remain largely elusive.

Methods: A total of 1126 Chinese advanced NSCLC patients from Xiangya hospital were screened by capture-based ultra-deep sequencing for KRAS mutation between January 2015 and December 2016. Survival analyses were performed using Kaplan-Meier analysis.

Results: Among the patients screened, 84 cases were detected with KRAS mutation (7.5%). All of them were non-squamous NSCLC and received pemetrexed plus platinum as the first-line treatment. The most frequent KRAS co-mutation genes were TP53 (29%), TP53/LKB1 (19%), and LKB1 (14%). Our data revealed that patients with KRAS co-mutation had poorer prognosis in comparison with those harboring single KRAS mutation. Furthermore, patients with KPL (KRAS mutated with TP53 and LKB1) subtype, which was a novel subtype, had the shortest progression-free survival (PFS) in all types of KRAS co-mutation patients (P < .0001). The PFS and overall survival (OS) of patients with KRAS mutation were inferior than those with KRAS mutation or KRAS mutation. Patients in KRAS type had significantly longer survival than those in KRAS type or KRAS type.

Conclusion: Our study revealed that concurrent genomic alterations can further stratify KRAS-mutant lung adenocarcinoma patients into various subgroups with distinctive therapeutic responses and differential survival outcomes. The KPL is a novel and less responsive subtype among KRAS-mutated NSCLC, and further investigation of effective treatment for this subtype is warranted.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.2682DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943152PMC
January 2020
-->